G.d. Searle & Company

Gerald M Walsh

Harman S Lowrie

Chi-Dean Liang

Earl G Burton

Christopher P Chengelis

A novel S diastereomer of an N.sup.6 -[(2-hydroxypropyl)aryl] adenosine, which diastereomer exhibits fewer CNS side effects than the racemate, but with no decrease in cardiovascular activity. The invention further provides for compositions incorporating the diastereomer, and methods of its use, as well as pharmaceutically acceptable salts thereof.

S-diastereomer of an n.sup.6 -((2-hydroxypropyl)aryl)adenosine and its

A novel R diastereomer of an N.sup.6 -[(2-hydroxypropyl)aryl]adenosine, which diastereomer exhibits fewer CNS side effects than the racemate, but with no decrease in cardiovascular activity. The invention further provides for compositions incorporating the diastereomer, and methods of its use as well as pharmaceutically acceptable salts thereof.

R-diastereomer of an N.sup.6 -[(2-hydroxypropyl)aryl]adenosine and its

1-(5-Amino-7-phenyl-[1,2,4] triazolo [1,5,c]pyrimidin-8-yl)-1, 2-ethan diol, a novel glycol of a triazolopyrimidine diuretic which is a metabolite and which exhibits fewer cardiotoxic side effects than the parent compound, but with no decrease in diuretic activity. The invention further provides for compositions incorporating the metabolite, and methods of its use as well as pharmaceutically acceptable salts thereof.

Diol metabolites of 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines

.beta.-Adrenergic receptor site activation by novel pyridinemethanol derivatives and pharmaceutical compositions and methods of use thereof are described.

Growing community of inventors

Lindenhurst, IL, United States of America

Gerald M Walsh